Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AMGEN FEBRUARY FEAST CLOSES WITH OBESITY GENE LICENSE; STOCK UP 8.5%

Executive Summary

Amgen is fattening its research prospects þ and steering investor attention away from takeover talk þ by licensing exclusive rights to a gene linked to obesity from the Rockefeller University. The Feb. 28 (Fat Tuesday) announcement of the agreement capped a strong month for Amgen on Wall Street, as the stock climbed 5-3/8 points (8.5%) in February to close at 69. Amgen is placing a large bet on the obesity gene project: the company will pay the university $20 mil. up front, milestone payments "several times that amount" and royalties on sales
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS025830

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel